Baird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11

Benzinga · 1d ago
Baird analyst Colleen Kusy maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $6 to $11.